RSV VACCINE BEARING ONE OR MORE P GENE MUTATIONS
US Application 63/023,949
Filed on 2020-05-13
Filed on 2020-05-13
Replication-Competent Adenovirus Type 4-HIV Env Vaccines And Their Use
US Application 63/063,810
Filed on 2020-08-10
Filed on 2020-08-10
Improvement Of HIV-neutralizing Antibodies By Modification Of The Heavy Chain FR3 Loop And Other Regions
US Application 62/940,572
Filed on 2019-11-26
Filed on 2019-11-26
2019-nCoV VACCINE
US Application 62/972,886
Filed on 2020-02-11
Filed on 2020-02-11
Improvement Of Trispecific Antibodies To HIV-1 By Engraftment Of The FR3 Loop Of VRC03 (FR3-03)
US Application 62/831,415
Filed on 2019-04-09
Filed on 2019-04-09
EPSTEIN-BARR VIRUS MONOCLONAL ANTIBODIES AND USES THEREOF
US Application 62/979,070
Filed on 2020-02-20
Filed on 2020-02-20
COMPOSITIONS INCLUDING IGG Fe MUTATIONS AND USES THEREOF
US Application 62/894,488
Filed on 2019-08-30
Filed on 2019-08-30
STABILIZED NOROVIRUS VIRUS-LIKE PARTICLES AS VACCINE IMMUNOGENS
US Application 63/091,824
Filed on 2020-10-14
Filed on 2020-10-14
MUMPS AND MEASLES VIRUS IMMUNOGENS AND THEIR USE
US Application 62/946,902
Filed on 2019-12-11
Filed on 2019-12-11
NON-NEUTRALIZING ANTIBODIES ELICITED BY RECOMBINANT LASSA-RABIES VACCINE ARE CRITICAL FOR PROTECTION AGAINST LASSA FEVER
US Application 62/691,413
Filed on 2018-06-28
Filed on 2018-06-28